Advancements in ocular gene therapy delivery: vectors and subretinal, intravitreal, and suprachoroidal techniques

Abstract

The success of treatment for IRD, paired with the promise of clinical research in acquired retinal diseases and in administration techniques, has raised the possibility of in-office gene therapy for common retinal disorders within the next 5 to 10 years.